Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib